Results 121 to 130 of about 64,427 (282)

ETV6::ABL1-Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous Treatment. [PDF]

Int J Mol Sci, 2023
Bochicchio MT, Marconi G, Baldazzi C, Bandini L, Ruggieri F, Lucchesi A, Agostinelli C, Sabattini E, Orsatti A, Ferrari A, Capirossi G, Servili C, Ghelli Luserna di Rorà A, Martinelli G, Simonetti G, Rosti G.   +15 more
europepmc   +1 more source

Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia [PDF]

, 2002
Hagop M. Kantarjian, Susan O’Brien, Jorge E. Cortés, Sergio Giralt, Mary Beth Rios, Jianqin Shan, Francis J. Giles, Deborah A. Thomas, Stefan Faderl, Marcos de Lima, Guillermo Garcia‐Manero, Richard E. Champlin, Ralph B. Arlinghaus, Moshe Talpaz   +13 more
openalex   +1 more source

Computational and mechanistic studies on the effect of galactoxyloglucan: Imatinib nanoconjugate in imatinib resistant K562 cells

Tumor Biology, 2017
Imatinib mesylate, a BCR/ABL fusion protein inhibitor, is the first-line treatment against chronic myelogenous leukemia. In spite of its advantageous viewpoints, imatinib still has genuine impediments like undesirable side effects and tumor resistance ...
Alphy Rose James, BS Unnikrishnan, R Priya, Manu M Joseph, TK Manojkumar, K Raveendran Pillai, R Shiji, GU Preethi, P Kusumakumary, TT Sreelekha   +9 more
doaj   +1 more source

Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate–resistant Bcr-Abl kinases [PDF]

, 2002
Markus Warmuth, Nicola Simon, Olga Mitina, Ruth Mathes, Doriano Fabbro, Paul W. Manley, Elisabeth Buchdunger, Karin Forster, Ismail Moarefi, Michael Hallek   +9 more
openalex   +1 more source

Poster Sessions

HemaSphere, Volume 9, Issue S1, June 2025.
wiley   +1 more source

Falla cardiaca asociada con el uso de imatinib mesilato: Reporte de un caso Heart failure associated to imatinib mesylate use: Case report

Revista Colombiana de Cardiología, 2008
La cardiotoxicidad por medicamentos es un evento cada vez más frecuente en la práctica clínica diaria. Inhibidores de la proteína de fusión Brc/Abl como el imatinib mesilato, son una nueva herramienta para el tratamiento de algunas neoplasias ...
Clara Saldarriaga, Jairo A Rendón, Juan M Senior   +2 more
doaj  

Serial monitoring of BCR–ABL by peripheral blood real‐time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia [PDF]

, 2002
Lihui Wang, Kevin Pearson, Lynne Pillitteri, Julia E. Ferguson, Richard E. Clark   +4 more
openalex   +1 more source

Rare KIT (CD117) expression in multiple myeloma abrogates the usefulness of imatinib mesylate treatment [PDF]

, 2018
Background: Imatinib mesylate blocks the tyrosine kinase activity of KIT (CD117) and is an effective treatment for gastrointestinal stromal tumors. In multiple myeloma, KIT expression has been detected by flow cytometry in about 33% of specimens, but no ...
Dirnhofer, S., Khanlari, B., Lugli, A., Nikolova, Z., Went, P.   +4 more
core  

Publication Only

HemaSphere, Volume 9, Issue S1, June 2025.
wiley   +1 more source

Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia

Brazilian Journal of Pharmaceutical Sciences
Adherence to imatinib mesylate improves clinical outcomes and promotes a reduction in health expenditure. However, treatment duration and lack of efficacy decrease adherence to pharmacotherapy, resulting in increased mortality associated with Chronic ...
Alexandra Rodrigues Alves, William Gustavo Lima, Michelly Martins Nagai, João Paulo Vilela Rodrigues, Lorena Rocha Ayres   +4 more
doaj   +1 more source